TMDX — TransMedics Group, Inc. stock price, charts and financials

Latest market price

86.66

-0.90-1.03%

Overview Short InterestFilings

TMDXQT46TransMedics Group, Inc.·NASDAQ

Overview Short InterestFilings

86.66-1.03%

News

Down 1.0% — TransMedics Group (NASDAQ:TMDX) Shares Up 4.5% After Insider Buying Activity (defenseworld.net).

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

NEOG+2.23%$12.83 IRTC-0.06%$111.75 AXGN-0.33%$45.29 UFPT-1.43%$275.41 BFLY+9.64%$7.96 INSP-0.01%$72.74 LIVN-0.92%$77.79 ITGR+0.17%$126.33

Snapshot

Index	-	P/E	22.45	EPS (ttm)	3.86	Insider Own	4.83%	Shs Outstand	34.56M	Perf Week	1.90%

Market Cap	3.00B	Forward P/E	37.68	EPS next Y	2.30	Insider Trans	-0.50%	Shs Float	33.54M	Perf Month	-4.44%

Enterprise Value	3.39B	PEG	0.42	EPS next Q	0.27	Inst Own	-	Short Float	24.09%	Perf Quarter	18.36%

Income	151.00M	P/S	4.48	EPS this Y	-61.57%	Inst Trans	-	Short Ratio	8.36	Perf Half Y	-23.45%

Sales	669.00M	P/B	5.78	EPS next Y	55.05%	ROA	10.36%	Short Interest	8.08M	Perf YTD	-28.76%

Book/sh	14.99	P/C	6.33	EPS next 5Y	53.93%	ROE	32.97%	52W High	156.00 -44.45%	Perf Year	-27.27%

Cash/sh	13.69	P/FCF	35.93	EPS past 3/5Y	-	ROIC	5.87%	52W Low	60.11 44.17%	Perf 3Y	50.24%

Dividend Est.	-	EV/EBITDA	28.25	Sales past 3/5Y	86.68% 87.65%	Gross Margin	58.69%	Volatility	6.08% 4.79%	Perf 5Y	169.97%

Dividend TTM	-	EV/Sales	5.07	EPS Y/Y TTM	282.18%	Oper. Margin	12.21%	ATR (14)	4.38	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	6.07	Sales Y/Y TTM	51.36%	Profit Margin	22.69%	RSI (14)	50.88	Recom	2.31

Dividend Gr. 3/5Y	-	Current Ratio	6.63	EPS Q/Q	-52.17%	SMA20	-1.73%	Beta	1.94	Target Price	96.86

Payout	0.00%	Debt/Eq	0.99	Sales Q/Q	21.02%	SMA50	4.53%	Rel Volume	0.75	Prev Close	87.56

Employees	898	LT Debt/Eq	0.96	Earnings	Nov 04	SMA200	-15.69%	Avg Volume	914.01K	Price	86.66

IPO Date	May 02, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.20% 3.23%	Net Debt/EBITDA	3.29	Volume	689,499	Change	-1.03%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-05-26	Reiterated	Robert W. Baird		$120 → $122
Aug-05-26	Reiterated	Canaccord Genuity	Buy	$124 → $95
Aug-05-26	Reiterated	Stifel Nicolaus		$80 → $65
Aug-03-26	Reiterated	Needham	Buy	$142 → $106
Jul-28-26	Initiated	UBS	Neutral	$80
Jul-06-26	Reiterated	Evercore ISI Group	Outperform	$155 → $90
Jun-18-26	Reiterated	Stifel Nicolaus		$75 → $80
May-26-26	Reiterated	Stifel Nicolaus		$85 → $75
May-06-26	Reiterated	Stifel Nicolaus		$130 → $85
May-06-26	Reiterated	Robert W. Baird		$157 → $140

Latest News· Times ET

Sep-15-26

Sep-15-2609:21PM

TransMedics Group (NASDAQ:TMDX) Shares Up 4.5% After Insider Buying Activitydefenseworld.net

10:01AM

TransMedics Group, Inc. (TMDX) Presents at 2026 Global Healthcare Conference - SlideshowSeekingAlpha

06:00AM

2 Stocks Down 28% and 34% to Buy and Holdfool.com

Sep-14-26

Sep-14-2602:31PM

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

11:00AM

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDXgurufocus.com

Sep-10-26

Sep-10-2612:05PM

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlookprnewswire.com

Sep-08-26

Sep-08-2606:14AM

TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price TargetBenzinga

Sep-07-26

Sep-07-2611:03AM

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com

Sep-03-26

Sep-03-2604:03PM

TransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells Investorsgurufocus.com

11:00AM

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?zacks.com

08:36AM

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?zacks.com

Sep-02-26

Sep-02-2606:10PM

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDXglobenewswire.com

Aug-31-26

Aug-31-2606:51PM

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDXprnewswire.com

12:05PM

TransMedics to Present at Upcoming September Investor Conferencesprnewswire.com

Aug-29-26

Aug-29-2609:25AM

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDXglobenewswire.com

Company

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	669	605	442	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	276	243	179	—	—	—	—	—	—
Gross Profit	392	363	262	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	212	185	169	—	—	—	—	—	—
Research and Development	93	69	56	—	—	—	—	—	—
Other Operating Expense	5	0	0	—	—	—	—	—	—
Operating Income	81	109	37	—	—	—	—	—	—
Interest Expense	20	14	14	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	12	13	13	—	—	—	—	—	—
Net Income Before Taxes	72	108	36	—	—	—	—	—	—
Income Taxes	-79	-83	0	—	—	—	—	—	—
Consolidated Net Income	151	190	35	—	—	—	—	—	—
Net Income From Continuing Operations	151	190	35	—	—	—	—	—	—
Net Income	151	190	35	—	—	—	—	—	—
EPS (Recurring)	4.42	5.60	1.07	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	4.42	5.60	1.07	—	—	—	—	—	—
EPS (Diluted)	3.86	4.87	1.01	—	—	—	—	—	—
EBITDA	120	148	70	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	22.45	24.98	61.73	—	—	—	—	—	—
Price To Sales Ratio	4.53	6.84	4.66	—	—	—	—	—	—
Gross Margin	58.59	60.00	59.28	—	—	—	—	—	—
Operating Margin	12.11	18.02	8.37	—	—	—	—	—	—
Net Margin	22.57	31.40	7.92	—	—	—	—	—	—
Shares Outstanding	35	34	33	—	—	—	—	—	—
Market Capitalization	3,033	4,136	2,058	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weill David	Director	Sep 11 '26	Buy	81.63	1,336	109,058	16,392	Sep 14
Gunderson Thomas J.	Director	Jun 15 '26	Option Exercise	2.21	19,285	42,620	26,266	Jun 17
Gunderson Thomas J.	Director	Jun 15 '26	Sale	75.06	9,624	722,377	16,642	Jun 17
Lovell Stephanie	Director	Mar 04 '26	Sale	149.62	1,193	178,497	2,866	Mar 06
Weill David	Director	Mar 04 '26	Option Exercise	14.20	3,571	50,708	15,705	Mar 06
Weill David	Director	Mar 04 '26	Sale	146.82	3,571	524,294	12,134	Mar 06
Hernandez Gerardo	Chief Financial Officer	Mar 04 '26	Sale	147.21	5,912	870,306	14,689	Mar 04
Hernandez Gerardo	Chief Financial Officer	Mar 04 '26	Option Exercise	71.17	7,236	515,001	20,601	Mar 04
Ranganath Anil P.	See remarks	Mar 02 '26	Sale	139.12	864	120,200	13,091	Mar 04
Hernandez Gerardo	Chief Financial Officer	Mar 02 '26	Sale	139.12	375	52,170	14,689	Mar 04
Corcoran Nicholas	See remarks	Mar 02 '26	Sale	139.12	2,966	412,630	29,831	Mar 04
Hernandez Gerardo	Chief Financial Officer	Dec 04 '25	Sale	139.62	920	128,450	15,064	Dec 05
Weill David	Director	Dec 03 '25	Option Exercise	14.20	5,000	71,000	17,134	Dec 05
Weill David	Director	Dec 03 '25	Sale	138.64	5,000	693,200	12,134	Dec 05
Ranganath Anil P.	See remarks	Nov 25 '25	Option Exercise	93.88	3,000	281,640	16,955	Nov 26

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.